Useful drugs in the management of ADPKD include small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, vasopressin V2-receptor (V2R) antagonists, and somatostatin analogues [9]. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.